ELIGLUSTAT TARTRATE

Search structure
Trade Names:
Synonyms:
Status: Approved (2014)
Entry Type: Small molecule
Molecule Category: Salt
UNII: N0493335P3
Parent Compound: ELIGLUSTAT

Structure
InChI Key KUBARPMUNHKBIQ-ZBPSDVLKSA-N
Smile CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2.O=C(O)C(O)C(O)C(=O)O
InChI
InChI=1S/2C23H36N2O4.C4H6O6/c2*1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20;5-1(3(7)8)2(6)4(9)10/h2*10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26);1-2,5-6H,(H,7,8)(H,9,10)/t2*19-,23-;/m11./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C50H78N4O14
Molecular Weight 959.19
AlogP 3.43
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 11.0
Polar Surface Area 71.03
Molecular species NEUTRAL
Aromatic Rings 1.0
Heavy Atoms 29.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Ceramide glucosyltransferase inhibitor FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Gaucher Disease 4 D005776 ClinicalTrials

Related Entries

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Gastrointestinal disorders
18.68
General disorders and administration site conditions
11.07
Nervous system disorders
8.54
Respiratory, thoracic and mediastinal disorders
7.54
Injury, poisoning and procedural complications
6.74
Skin and subcutaneous tissue disorders
6.4
Musculoskeletal and connective tissue disorders
6.27
Cardiac disorders
5.8
Infections and infestations
5.2
Vascular disorders
4.6
Investigations
3.87
Psychiatric disorders
3.87
Metabolism and nutrition disorders
2.2

Cross References

Resources Reference
ChEMBL CHEMBL4297066
FDA SRS N0493335P3
PubChem 52918379
CONTENTS